Publications en collaboration avec des chercheurs de Aarhus University Hospital (9)

2023

  1. Corrigendum to “Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis” [J Hepatol 79(4) (2023 Oct) 967–976] (Journal of Hepatology (2023) 79(4) (967–976), (S0168827823003513), (10.1016/j.jhep.2023.05.022))

    Journal of Hepatology

  2. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 967-976

2022

  1. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

    Journal of Hepatology, Vol. 77, Núm. 6, pp. 1554-1563

2020

  1. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

    Modern Pathology, Vol. 33, Núm. 5, pp. 792-801

2019

  1. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project

    Lung Cancer, Vol. 131, pp. 95-103

2018

  1. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

    Journal of Thoracic Oncology, Vol. 13, Núm. 3, pp. 413-425

  2. Urea cycle dysregulation in non-alcoholic fatty liver disease

    Journal of Hepatology, Vol. 69, Núm. 4, pp. 905-915

2017

  1. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project

    Lung Cancer, Vol. 111, pp. 143-149

2014

  1. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project

    Journal of Clinical Oncology, Vol. 32, Núm. 25, pp. 2780-2787